ATE523591T1 - Verwendung eines ansatzes auf rnai-basis mit galectin-1 als ziel zur krebsbehandlung - Google Patents
Verwendung eines ansatzes auf rnai-basis mit galectin-1 als ziel zur krebsbehandlungInfo
- Publication number
- ATE523591T1 ATE523591T1 AT06707489T AT06707489T ATE523591T1 AT E523591 T1 ATE523591 T1 AT E523591T1 AT 06707489 T AT06707489 T AT 06707489T AT 06707489 T AT06707489 T AT 06707489T AT E523591 T1 ATE523591 T1 AT E523591T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- hodgkin
- lymphoma
- melanoma
- head
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 102000000795 Galectin 1 Human genes 0.000 title abstract 2
- 108010001498 Galectin 1 Proteins 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000032612 Glial tumor Diseases 0.000 abstract 4
- 206010018338 Glioma Diseases 0.000 abstract 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 4
- 201000010536 head and neck cancer Diseases 0.000 abstract 4
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 4
- 208000030758 lung non-Hodgkin lymphoma Diseases 0.000 abstract 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 4
- 201000001441 melanoma Diseases 0.000 abstract 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 4
- 201000002528 pancreatic cancer Diseases 0.000 abstract 4
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 108091030071 RNAI Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67033405P | 2005-04-12 | 2005-04-12 | |
PCT/EP2006/002170 WO2006108474A2 (en) | 2005-04-12 | 2006-03-09 | Use of a galectin-1-trageted rnai-based approach for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE523591T1 true ATE523591T1 (de) | 2011-09-15 |
Family
ID=36933483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06707489T ATE523591T1 (de) | 2005-04-12 | 2006-03-09 | Verwendung eines ansatzes auf rnai-basis mit galectin-1 als ziel zur krebsbehandlung |
Country Status (9)
Country | Link |
---|---|
US (1) | US7964575B2 (de) |
EP (1) | EP1874930B1 (de) |
JP (1) | JP5242377B2 (de) |
CN (1) | CN101228274A (de) |
AT (1) | ATE523591T1 (de) |
AU (1) | AU2006233522A1 (de) |
BR (1) | BRPI0612334A2 (de) |
CA (1) | CA2604288C (de) |
WO (1) | WO2006108474A2 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9375440B2 (en) * | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US8324367B2 (en) * | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
WO2009012382A2 (en) * | 2007-07-17 | 2009-01-22 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the modulation of immune responses using galectin-1 |
WO2009012384A2 (en) * | 2007-07-17 | 2009-01-22 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1 |
BRPI0919975A2 (pt) * | 2008-10-29 | 2015-12-15 | Bg Medicine Inc | imunoensaio para galectina-3 |
CN101984056B (zh) * | 2009-07-10 | 2013-04-17 | 四川大学 | 人黑色素瘤细胞相关的长非编码rna的rna干扰靶点rna及用途 |
CN101619312B (zh) * | 2009-07-10 | 2011-04-20 | 四川大学 | 人黑色素瘤细胞特异表达的长非编码rna序列及其用途 |
EP2499159B1 (de) * | 2009-11-13 | 2017-01-04 | Dana-Farber Cancer Institute, Inc. | Zusammensetzungen, kits und verfahren zur diagnose, prognose, überwachung, behandlung und modulierung von auf transplantationen folgenden lymphoproliferativen erkrankungen und hypoxievermittelten angiogeneseerkrankungen mithilfe von galectin-1 |
US10314917B2 (en) | 2013-03-15 | 2019-06-11 | The Brigham And Women's Hospital, Inc. | Targeted polymeric inflammation-resolving nanoparticles |
JP6581982B2 (ja) | 2013-07-24 | 2019-09-25 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | ガレクチン−1(gal1)を中和するための抗gal1モノクローナル抗体およびその断片 |
US11576976B2 (en) * | 2015-01-21 | 2023-02-14 | D. R. NANO Co., Ltd. | Method of treating cancer by using siRNA nanocomplexes |
CN113633656A (zh) * | 2015-02-25 | 2021-11-12 | 柏业公司 | 包含微小核糖核酸作为活性成分的用于治疗癌症的药物组合物 |
GB201520600D0 (en) * | 2015-11-23 | 2016-01-06 | Univ Leuven Kath | Treatment of central nervous tumours |
CN107540738B (zh) * | 2017-04-10 | 2020-04-24 | 清远职业技术学院 | 一种香港巨牡蛎半乳凝素ChGalectin及其制备方法和应用 |
CN112672765A (zh) | 2018-06-29 | 2021-04-16 | 格莱科斯生物医药公司 | 结合物 |
US20230038373A1 (en) | 2019-12-18 | 2023-02-09 | Glykos Biomedical Oy | Stabile conjugate |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
EP1325116A2 (de) * | 2000-10-04 | 2003-07-09 | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. | Isoprenoid-abhängige ras-ankerproteine (idra) |
US20020173478A1 (en) * | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
WO2003070912A2 (en) * | 2001-06-06 | 2003-08-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2002097114A2 (en) * | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv |
US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
WO2004012817A2 (en) | 2002-07-31 | 2004-02-12 | Kylix B.V. | Use of genes identified to be involved in tumor development for the development of anti-cancer drugs |
US20070178458A1 (en) * | 2003-09-05 | 2007-08-02 | O'brien Philippa | Methods of diagnosis and prognosis of ovarian cancer II |
-
2006
- 2006-03-09 AT AT06707489T patent/ATE523591T1/de not_active IP Right Cessation
- 2006-03-09 EP EP06707489A patent/EP1874930B1/de not_active Not-in-force
- 2006-03-09 CA CA2604288A patent/CA2604288C/en active Active
- 2006-03-09 JP JP2008505747A patent/JP5242377B2/ja not_active Expired - Fee Related
- 2006-03-09 AU AU2006233522A patent/AU2006233522A1/en not_active Abandoned
- 2006-03-09 WO PCT/EP2006/002170 patent/WO2006108474A2/en active Application Filing
- 2006-03-09 CN CNA2006800163765A patent/CN101228274A/zh active Pending
- 2006-03-09 US US11/911,342 patent/US7964575B2/en not_active Expired - Fee Related
- 2006-03-09 BR BRPI0612334-1A patent/BRPI0612334A2/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2604288A1 (en) | 2006-10-19 |
JP5242377B2 (ja) | 2013-07-24 |
WO2006108474A3 (en) | 2006-12-21 |
BRPI0612334A2 (pt) | 2009-01-27 |
EP1874930B1 (de) | 2011-09-07 |
US7964575B2 (en) | 2011-06-21 |
AU2006233522A1 (en) | 2006-10-19 |
US20100120891A1 (en) | 2010-05-13 |
CN101228274A (zh) | 2008-07-23 |
JP2008535504A (ja) | 2008-09-04 |
WO2006108474A2 (en) | 2006-10-19 |
CA2604288C (en) | 2021-07-06 |
EP1874930A2 (de) | 2008-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE523591T1 (de) | Verwendung eines ansatzes auf rnai-basis mit galectin-1 als ziel zur krebsbehandlung | |
Kang et al. | Oxidative stress, Nrf2, and epigenetic modification contribute to anticancer drug resistance | |
Pan et al. | Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1 | |
WO2005100998A3 (de) | Membrane markers for use in cancer diagnosis and therapie | |
WO2008020596A3 (en) | Treating or preventing cancers over-expressing reg4 or kiaa0101 | |
NZ626867A (en) | Compositions and methods for the treatment of infections and tumors | |
WO2016106400A3 (en) | Rna interference agents for gst-pi gene modulation | |
WO1999022773A3 (en) | Sequences for targeting metastatic cells | |
ATE420160T1 (de) | Modifizierte rekombinante vacciniaviren, verwendungen davon | |
NZ591137A (en) | Methods and systems for predicting response of cells to a therapeutic agent | |
BRPI0808940A8 (pt) | anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor | |
WO2005116259A3 (en) | Use of gene expression profiling to predict survival in cancer patient | |
NO20055209L (no) | Peptabody for cancerbehandling | |
WO2007144985A1 (ja) | Rpn2遺伝子発現抑制剤の用途 | |
UA99602C2 (ru) | Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток | |
MX2009004890A (es) | Direccionamiento de subunidades alpha-1 o alpha-3 de na+, k+-atpasa en el tratamiento de enfermedades proliferativas. | |
MX2009009816A (es) | Anticuerpos monoclonales para el tratamiento del cancer. | |
Gao et al. | LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer | |
WO2005090572A3 (en) | Compositions and methods for treating pancreatic cancer | |
MX2021001517A (es) | Terapia basada en microarn dirigida contra canceres positivos para proteina citosolica de linfocito 1 (lcp-1). | |
WO2004074437A3 (en) | Compositions and methods for cancer immunotherapy | |
EP2114431A4 (de) | Zusammensetzung mit arazym zur prävention und behandlung von krebs | |
GB0418388D0 (en) | Cell therapy | |
WO2013066485A3 (en) | Compositions and methods for treatment of metastatic cancer | |
HK1074840A1 (en) | Novel dithiolopyrrolones with therapeutic activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |